OncoVista’s AdnaGen Test (OTC:OVIT)
OncoVista Innovative Therapies, Inc (OTC:OVIT) reported that two of their proprietary products, AdnaTest BreastCancer and AdnaTest ETM1/Stem Cell were being evaluated in Germany by the Department of Gynecology and Obstetrics and Internal Medicine at University Hospital Essen, University of Duisburg-Essen and University Hospital of Tuebingen and it was found that the research has been accepted for publication in the prestigious publication, Cancer Research. The researchers were testing the theory that cancer cells circulating in the bloodstream may be linked with the stem cell like tumor cells that are thought to be the active source of metastatic spread from primary tumors. The researchers were also testing the theory that these cells may undergo physical and biological changes which allow these cells to travel and metastize without getting affected by conventional cancer therapies.
The Company’s AdnaTest BreastCancer product developed and produced by OncoVista’s wholly owned German subsidiary AdnaGen AG is currently commercially available and CE marked in Europe. OncoVista Innovative Therapies, Inc. is very excited by the results of the findings. Dr. Alexander L. Weis, President and C.E.O. of OncoVista Innovative Therapies, Inc. said that AdnaTest™ BreastCancer and the AdnaTest EMT1/StemCell, can lead to better evaluation sooner and more cost-effective treatments with less, unnecessary suffering and toxic side-effects. In addition, it provides innovative tools for the development of novel targeted oncology drugs and companion diagnostics for evaluation of their performance.
Related Articles:
I would like to know how I take advantage of this in New York City.